Dabigatran affects thrombin-dependent platelet aggregation after a week-long therapy.

Area of Science:

• Pharmacology and Thrombosis Research
• Cardiovascular Medicine

Background:

• Dabigatran is a direct thrombin inhibitor used for anticoagulation.
• Bleeding is a primary adverse event associated with dabigatran therapy.
• Understanding dabigatran's effects on platelet function is crucial for assessing bleeding risk.

Purpose of the Study:

• To investigate the in vitro effects of dabigatran on platelet aggregation in patients with atrial fibrillation (AF).
• To determine if dabigatran influences platelet function, potentially impacting bleeding risk.

Main Methods:

• Evaluated 32 AF patients on dabigatran and 18 healthy blood donors.
• Assessed light transmittance platelet aggregation (LTA) using gamma-thrombin.
• Performed LTA at baseline and two hours post-dabigatran intake in the patient group.

Main Results:

• Thrombin-induced platelet aggregation was significantly reduced two hours after dabigatran intake (9% ± 6%) compared to baseline (29% ± 21%).
• Baseline platelet aggregation in dabigatran-treated patients was significantly lower than in healthy volunteers (29% ± 21% vs. 89% ± 8%).
• This reduction in baseline platelet aggregation was significant only in patients treated with dabigatran for over one week.

Conclusions:

• Dabigatran therapy leads to reduced thrombin-induced platelet aggregation in non-valvular AF patients.
• The antiplatelet effect of dabigatran becomes significant after at least one week of continuous therapy.
• Findings suggest a potential impact on bleeding risk, warranting further investigation.